Grant: Alliance Grants
École Polytechnique de Montréal
$50,000.00
PERSONALIZED COVID-19 DIAGNOSTICS WITH IMMUNOPLASMONIC MICROSCOPY _x000d_ _x000d_ _x000d_ _x000d_ _x000d_
EF 2020-21
Résumé
At this time, healthcare system is facing heavy challenges requiring new and urgent tools to handle and relief severe impacts of COVID-19 outbreak. Personalized access to affordable, high-quality diagnostic tools for the detection of infectious diseases, including SARS-CoV-2, in resource-limited settings and outside the hospital environment, is imperative. In this project, we propose an alternative and promising solution for rapid clinical and personalized COVID-19 diagnosis. High efficiency and sensitivity of the proposed device is ensured by the use of an elaborated Imaging Localized Surface Plasmon Resonance (ILSPR) biosensing technology. The key innovation here is the dual utilization of specifically functionalized proprietary own immunoplasmonic nanoparticles (NPs). Due to their unique optical and chemical properties, plasmonic NPs, which are precisely functionalized by specific biomolecules can perform as (I) selective biomarkers of target viruses (i.e., the detection of expressed spike proteins), and as (II) optically active tags easily detectable and quantifiable under our simplified optical imaging system (i.e., dark-field side-illumination microscopy developed in our laboratory). Our well-organized research team, including, chemists, biologists, engineers, and clinical biochemist from the Maisonneuve-Rosemont Hospital with a collaboration of the innovation company (Allied Scientific Medical) joint their efforts to develop a professional cost-effective, plasmonic biosensing system to diagnose patients outside of centralized facilities. Taking advantage of the widespread distribution of personal electronic devices (i.e., smartphones and tablets) equipped with an effective optical sensor and communication capability, the proposed ILSPR plasmonic biosensor can also be considered as the hand-held portable personalized diagnostic device capable to obtain accurate results in less than 10 minutes and dispatches it to specialists for a precise analysis or confirmation through a telemedicine network.
Programme
Alliance Grants
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
555170-2020
Name nom
Meunier, Michel
Department département
Génie physique
Organization id
64
Institution établissement
École Polytechnique de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
50000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
PERSONALIZED COVID-19 DIAGNOSTICS WITH IMMUNOPLASMONIC MICROSCOPY _x000d_
_x000d_
_x000d_
_x000d_
_x000d_
Keyword
NSERC
Application summary
At this time, healthcare system is facing heavy challenges requiring new and urgent tools to handle and relief severe impacts of COVID-19 outbreak. Personalized access to affordable, high-quality diagnostic tools for the detection of infectious diseases, including SARS-CoV-2, in resource-limited settings and outside the hospital environment, is imperative. In this project, we propose an alternative and promising solution for rapid clinical and personalized COVID-19 diagnosis. High efficiency and sensitivity of the proposed device is ensured by the use of an elaborated Imaging Localized Surface Plasmon Resonance (ILSPR) biosensing technology. The key innovation here is the dual utilization of specifically functionalized proprietary own immunoplasmonic nanoparticles (NPs). Due to their unique optical and chemical properties, plasmonic NPs, which are precisely functionalized by specific biomolecules can perform as (I) selective biomarkers of target viruses (i.e., the detection of expressed spike proteins), and as (II) optically active tags easily detectable and quantifiable under our simplified optical imaging system (i.e., dark-field side-illumination microscopy developed in our laboratory). Our well-organized research team, including, chemists, biologists, engineers, and clinical biochemist from the Maisonneuve-Rosemont Hospital with a collaboration of the innovation company (Allied Scientific Medical) joint their efforts to develop a professional cost-effective, plasmonic biosensing system to diagnose patients outside of centralized facilities. Taking advantage of the widespread distribution of personal electronic devices (i.e., smartphones and tablets) equipped with an effective optical sensor and communication capability, the proposed ILSPR plasmonic biosensor can also be considered as the hand-held portable personalized diagnostic device capable to obtain accurate results in less than 10 minutes and dispatches it to specialists for a precise analysis or confirmation through a telemedicine network.